David Peretz
Overview
Explore the profile of David Peretz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith M, Chow J, Huang R, Omar M, Ebadi M, Wong P, et al.
Can Liver J
. 2023 Dec;
5(4):507-512.
PMID: 38144413
Prior studies have assessed risk factors and clinical outcomes in liver transplant (LT) recipients infected with COVID-19 globally; however, there is a paucity of Canadian data. Our multicentre study aims...
2.
Dascal R, Wiebe C, Niazi M, Worobetz L, Bhanji R, Knowles C, et al.
Can Liver J
. 2023 Dec;
5(4):466-475.
PMID: 38144402
Post-transplant diabetes mellitus (PTDM) occurs in 10%-40% of liver and renal transplant recipients. Whether the risk factors for PTDM in liver and renal transplant recipients are similar and whether Indigenous...
3.
Peretz D, Faisal N, Uhanova J, Schacter I, McAlpine D, Knowles C, et al.
Can Liver J
. 2023 Nov;
6(3):353-357.
PMID: 38020189
Background: Post liver transplant diabetes mellitus (PLTDM) occurs in 10-40% of liver transplant recipients and is associated with increased morbidity and mortality. An important cause of PLTDM is tacrolimus induced,...
4.
Hanumanthappa N, Cho B, McKay A, Peretz D, Minuk G, Lambert P, et al.
Can Liver J
. 2022 Aug;
3(2):194-202.
PMID: 35991857
Background: Hepatocellular carcinoma (HCC) has a very poor survival rate, especially for those who do not receive a potentially curative therapy. Methods: Treatment details were collected for 320 HCC patients...
5.
Peretz D, On N, Miller D, Kim R, Franklin C, Dascal R, et al.
Transpl Int
. 2021 Jul;
34(11):2266-2273.
PMID: 34318518
Patient ethnicity may influence the pharmacokinetics (PK) of tacrolimus. Because the Canadian First Nations (FN) constitute a large and increasing segment of the liver transplant population, we undertook to determine...
6.
Peretz D, Grubert Van Iderstine M, Bernstein M, Minuk G
Transplant Direct
. 2020 Jul;
6(6):e558.
PMID: 32607424
Background: Patients who travel long distances to undergo liver transplantation have limited opportunities to develop confidence in their new healthcare providers and experience fewer support visits from family and friends...
7.
Iluz-Freundlich D, Samad N, Miles D, Osiowy C, Kaita K, Wong S, et al.
Dig Dis Sci
. 2020 Feb;
66(1):257-262.
PMID: 32034604
Background: Acute exacerbations of chronic hepatitis B virus (HBV) infections can occur in HBV-infected, hepatitis e antigen (HBeAg)-negative patients in the absence of recent withdrawal of antiviral or immunosuppressive therapies....
8.
Gong A, Leitold S, Uhanova J, Dolovich C, Medd P, Peretz D, et al.
Clin Invest Med
. 2018 Jul;
41(2):E37-E42.
PMID: 29959881
Background: Some patients with alcohol-induced liver failure will succumb to their disease prior to demonstrating compliance with the six months abstinence rule for liver transplantation. Purpose: The purpose of this...
9.
Minuk G, Iliant V, Zhou N, Kaita K, Wong S, Peretz D, et al.
Liver Int
. 2017 Dec;
38(6):1110-1116.
PMID: 29193593
Background & Aims: The impact of nonalcoholic fatty liver disease (NAFLD) on the natural history of primary biliary cholangitis (PBC) has yet to be described. The aim of this study...
10.
Herder C, de Las Heras Gala T, Carstensen-Kirberg M, Huth C, Zierer A, Wahl S, et al.
Arterioscler Thromb Vasc Biol
. 2017 Apr;
37(6):1222-1227.
PMID: 28428221
Objective: Interleukin (IL)-1β represents a key cytokine in the development of cardiovascular disease (CVD). IL-1β is counter-regulated by IL-1 receptor antagonist (IL-1RA), an endogenous inhibitor. This study aimed to identify...